Ulcerative colitis, Crohn'
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1)IBD patients with previous consultation from Jan. 1st, 2008 to Dec. 31st, 2020 2) IBD patients whose IBD-associated neoplasia or malignancy in other organs which had been confirmed by endoscopy, CT, histological analysis, etc.
Exclusion criteria
Exclusion criteria: 1)Patients without adequate confirmation of neoplasms. 2)Patients whom investigators considered inappropriate to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence and breakdown of IBD-associated neoplasia or malignancy in other organs | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Factors associated with a poor prognosis in patients with IBD-associated neoplasia or malignancy in other organs 2)Diagnostic value of image-enhanced endoscopy in patients with IBD-associated neoplasia 3)The effect of immunomodulatory or biologics on the risk of IBD-associated neoplasia or malignancy in other organs 4)Outcome of the endoscopic or surgical treatment for IBD-associated neoplasia | — |
Countries
Japan
Contacts
Kyushu University Hospital Department of Endoscopic Diagnositics and Therapeutics